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Background: Refugees are vulnerable to tuberculosis (TB) infection. Tracking of
program performance is needed to improve TB care and prevention. The objective
of this study was to assess the trends of TB treatment outcomes of notified cases in
three refugee camps in Sudan from 2014 to 2017.
Methods: This study was a historical cohort study. Sex, age, type of TB, TB patient
category, and treatment outcome of all TB cases registered in three refugee camps
(Al Kashafa, Shagarab, Wadsherify) from January 1, 2014 to December 31, 2017 were
collected from the TB register. Multivariable logistic regression was performed to
explore factors for unsuccessful TB treatment.
Results: A total of 710 TB cases of which 53.4% were men, 22.1% children (<15
years), and 36.2% extrapulmonary TB (EPTB) were registered. Overall, the TB treatment
success rate was 75.7% with a declining trend from 86.2% in 2015 to 63.5% in 2017. On
average, 11.4% were lost to follow-up (LTFU), 6.6% died, 5.9% were not evaluated, and
in 0.3% the treatment failed. Being 15–24 years old and having EPTB were significantly
associated with unsuccessful treatment outcome.
Conclusion: The treatment success rate in the refugee camp in 2017 (63.5%) was far
lower than the national treatment success rate (78%) and the End TB global target
(≥90%) that needs to be improved. LTFU, died, and not evaluated outcomes were high
which indicated the necessity to improve the TB treatment program.
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1. Introduction
Tuberculosis (TB) is a major public health challenge around the globe. According to
the World Health Organization (WHO) report, in 2017, 10 million TB cases and 1.6
million TB deaths (HIV-negative) were recorded worldwide. In Sudan, the estimated
TB incidence and mortality rate (HIV-negative) per 100,000 population in 2017 were
77 and 12, respectively [1]. Although, TB burden has been falling in the past 20 years
worldwide [1], it still remains a primary cause of death from a single infectious agent
since 2011 [1, 2].
TB is more severe among refugees and internally displaced populations (IDPs) who
are at risk to acquire and develop active TB infection [3–6], multi-drug-resistant TB
(MDR-TB) [7], as well as low TB treatment success [8, 9]. The reasons for higher TB
burden in refugees and other key populations are poor shelter, poor nutritional status,
and inadequate TB care and prevention [3–6, 10].
By the end of 2018, nearly 71 million refugees and asylum seekers were registered
globally [11]. Majority (>86%) of refugees are from and stay within developing countries
where the TB burden is higher [12]. Studies have shown an increase in the prevalence
of TB [13, 14] and TB case notification [14, 15] when the number of refugee population
increases. Thus, key populations such as refugees have been given special focus in
the Stop TB [16] and End TB [2] WHO strategic documents so as to achieve the global
targets by 2035.
Sudan (with a population size of 41 million in 2017) is among the countries with high
TB incidence rates (≥20/100,000 population) in the world [1]. Sudan has a long history of
hosting refugees. By the end of 2019, the country had hosted >1.1 million refugees living
in camps and out of camps (70%) in over 130 localities across the country’s 18 states
[17]; 74, 11, and 8.5% of the refugees in Sudan originate from South Sudan, Eritrea, and
Syria, respectively, and the remaining are from Ethiopia, Democratic Republic of Congo
(DRC), Chad, Somalia, and Yemen. The number of refugees and asylum seekers in
Sudan increased continuously during the study period, from 437,518 in 2014 to 924,810
in 2017 [17].
The aforementioned pieces of evidence [13–17] indicate that TB is one of the main
health problems in the refugee camps of Sudan. Hence, periodic review of TB program
performance in the refugee camps is needed to address the gaps and improve the
implementation of TB care and prevention program.
TB treatment outcome is the most important global indicator to assess the overall
quality of TB program and the effectiveness of TB treatment program in particular [18, 19].
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As defined in the End TB strategy, the 2020 TB treatment success rate target is at least
90% [2]. Generally, TB treatment success in the refugee population can be affected
by factors including less adherence to treatment, death, noncompletion due to lost to
follow-up (LTFU), malnutrition, and other coexisting illnesses such as HIV coinfection
[8, 20, 21]. Studies showed lower treatment success rate among refugees in Ethiopia
(75.1%) [22] and in refugees hosted in different countries (ranging from 63.6 to 77.5%)
[23–28].
The TB program in Sudan including in the refugee camps is guided by the National TB
Program (NTP), under the Communicable and Non-Communicable Disease Department,
in the Ministry of Health (MOH) [22]. The NTP in Sudan has a surveillance system but
it largely focuses on the government-owned health facilities run by Federal and State
Minsters of Health. However, there is no specific study on the trends of treatment
outcome and factors associated with unsuccessful treatment outcome in the refugee
camps. Hence, this study aimed to investigate trends of TB treatment outcomes of
notified TB cases and assess factors for unsuccessful treatment outcomes in three
refugee camps in Sudan from 2014 to 2017.
2. Materials and Methods
2.1. Study settings and participants
In Sudan, TB program in the refugee camps is led and coordinated by the NTP and is
implemented according to the national TB guideline [22]. The data collection for the TB
surveillance system occurs at TB management units (TBMUs) that utilize patient cards
and registers [22].
This study was a refugee health facility based which used Unit TB registers in the
refugee camps as data source. According to the inclusion criteria, all refugee health
facilities which provided TB diagnosis and treatment at least since January 2017 were
included. Thus, three health facilities which fulfilled the inclusion criteria in three refugee
camps (Al Kashafa, Shagarab, Wadsherify) located in White Nile and Kassala states were
included. The study participants were all TB cases registered in these three refugee
camps from January 1, 2014 to December 31, 2017.
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2.2. Study design and data collection
This study was a historical cohort study. Variables included in the Unit TB register such
as sex, age, type of TB, TB patient category, and treatment outcome of all TB cases
registered in three refugee camps (Al Kashafa, Shagarab, Wadsherify) were collected.
Data collection tool was developed and pretested. Nurses and program officers were
recruited as data collectors and supervisors, respectively, and received training on data
collection tools including practical exercise. Data were collected from January to April
2019.
Data quality was assured through provision of training to data collectors and super-
visors and undertaking daily field supervision by the field supervisors. In addition, 10%
of the data collected were randomly selected and recollected by the field supervisors
and checked page by page.
2.3. Data analysis
Epi-info statistical software version 7 was used for data entry, and data were exported
to STATA version 13 (Stata Corp, College Station, TX, USA) for analysis. Frequencies,
proportions, and ratios were calculated to describe treatment outcome variables.
Bivariate and multivariable logistic regression analysis were done to assess factors
associated with unsuccessful treatment outcome. The independent variables used
were age, sex, baseline weight, type of TB, category of TB patient, refugee camps,
year of treatment, and HIV infection. Odds ratios (OR) with 95% confidence interval was
used to assess the strength of association between variables. Statistical significance
level was considered at a P-value < 0.05.
2.4. Operational definitions
The operational definitions of TB cases and TB treatment outcome categories in this
study are based on the National TB management guideline in Sudan [29] and the WHO
document [30] included in Supplement 1.
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3. Results
3.1. General characteristics
Table 1 shows the general characteristics of the study participants. During the study
period, 710 TB cases of all forms were notified in Al Kashafa, Wadsherify, and Shagarab
refugee camps. More specifically, the notified TB cases in Al Kashafa, Shagarab, and
Wadsherify refugee camps were 334, 206, and 170, respectively.
Of these TB cases, 377 (53.4%) were males and 329 (46.6%) females. The male-to-
female ratio (M: F) of the notified cases increased from 1:1 in 2014 to 1.7:1 in 2016 and
then declined to 1.1:1 in 2017. The mean (standard deviation, SD) age was 34.1 (21.4)
years. Among the notified cases, children aged <15 years and adults aged ≥15 years
constituted 22.1 and 77.9%, respectively. By refugee camp, majority, 334 (47.0%), of the
TB cases were from Al Kashafa, 206 (29.0%) were from Shagarab, and 170 (23.9%) were
from Wadsherify.
3.2. TB cases by diagnostic and age categories
Overall, the number of notified TB cases in the camps increased from 143 in 2014 to
341 cases in 2017. We further analyzed the notified cases disaggregated by diagnostic
category and gender (Table 1). From 2014 to 2017, the proportion of Extrapulmonary TB
(EPTB) increased from 29.3 to 39.3%.
Among the notified TB cases, the proportion of smear-positive PTB remained lower
and decreased from 37.8% in 2014 to 24.9% in 2017 (Table 1; Figure 1). Similarly, the
proportion of bacteriologically confirmed cases among new and relapse PTB patients
decreased from 52.6% in 2014 to 40.2% in 2017 (Table 1).
Over the study period, the difference in the proportion of notified cases by age was
observed (Table 1). From 2014 to 2017, the percentage of TB accounted by children (<15
years) increased from 8.4 to 34.3%, while the share of the younger age group (15–34
years) decreased from 39.9 to 27.3%.
3.3. Notified TB cases by HIV status
Among the 710 notified TB cases in the four-year period, HIV testing was done for
42.7%. The proportion of notified TB cases who did not receive HIV test and results
increased from 30% in 2015 to 62.5% in 2017. The TB–HIV coinfection rate decreased
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Figure 1: Trends of notified TB cases (bar) by diagnostic category (line) in Al Kashafa, Wadsherify, and
Shagarab refugee camps, Sudan, 2014–2017.
from 7.1% (4/56) in 2015 to 4.7% (6/128) in 2017 (Table 1). All identified HIV-positive TB
cases in each year were put on ART.
3.4. TB treatment outcomes from 2014 to 2017
Treatment outcome was determined for 143, 80, 146, and 341 TB cases of all forms
that were notified in 2014, 2015, 2016, and 2017, respectively (Table 2). The treatment
success rate remained lower at a range 63.5–82.9% (increasing gradually from 78.3%
in 2014 to 82.9% in 2016 then decreasing to 63.5% in 2017). On average, 18.7% were
cured, 57.0% treatment completed, 0.3% treatment failed, 11.4% LTFU, 6.6% died, and
5.9% not evaluated. From 2015 to 2017, there was an increase in the percentage of LTFU
(from 3.8 to 15.8%) and dead (3.8 to 8.5%) patients, but a decrease in the percentage
of cured patients (from 26.6 to 10.6%).
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3.5. Demographic and clinical characteristics associated with
unsuccessful TB treatment outcomes in Sudan refugee camps
(2014–2017)
Using a simple bivariate logistic regression analysis, age group and type of TB were
seen to be associated with unsuccessful treatment outcomes. More specifically, age
15–24 years [OR = 0.4, 95% CI: 0.2–0.8, P = 0.01], 25–34 years [OR = 0.5, 95% CI:
0.3–0.9, P = 0.02], 45–54 years [OR = 0.5, 95% CI: 0.2–0.96, P = 0.04], smear-positive
pulmonary TB (PTB+) [OR = 0.5, 95% CI: 0.3–0.8, P = 0.01], and EPTB [OR = 0.5, 95%
CI: 0.3–0.8, P = 0.006] were associated with unsuccessful treatment outcomes.
After adjusting for potential confounders by multivariable modelling, only age groups
15–24 years [adjusted odds ratio (aOR) = 0.4, 95% CI: 0.2–0.9, P = 0.02] and being an
EPTB case [aOR = 0.5, 95% CI: 0.3–0.9), P= 0.009] were associated with unsuccessful
treatment outcome (Table 3).
4. Discussion
The findings of this study generate evidence on trends of treatment outcomes of notified
case during the study period (2014–2017), which is relevant to improve the quality of TB
program in Al Kashafa, Wadsherify, and Shagarab refugee camps in Sudan.
4.1. Notified TB cases
In countries with good TB diagnoses and reporting system, case notifications can be
used as a proxy for TB incidence estimates [19]. Moreover, bacteriologic diagnosis of TB
allows patients to be correctly diagnosed and started on the most effective treatment
regimen. In this study, the absolute number of notified new and relapse cases showed
an increment during the study period which could be due to the increment of refugees
or new influxes following the conflicts in South Sudan. Similarly, an increase in notified
TB cases (from 138 cases in 2014 to 588 in 2017) was reported in refugee population
hosted in refugee camps in Ethiopia [22]. In contrast, notified incident TB cases among
Syrian refugees in Jordan has declined from 79 cases in 2013 to 58 cases in 2015 [28].
In this study, 45.3% of the new and relapse PTB cases in the refugee camps in 2017
were bacteriologically confirmed, which is lower than the 2018 WHO report for Sudan
(49%), African Region (66%), and for the globe (56%) [1], and the End TB global target
where 80% of the new and relapse TB patients need to be bacteriologically confirmed
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by 2020 [2]. The low proportion of bacteriologically confirmed cases may reflect gaps
in capacity for accurate diagnosis.
Analyzing the notified TB cases by type of TB is important for targeted interventions.
In this study, proportion of EPTB increased from 29.4% in 2014 and reached 39.3% by
2017. This is higher than the proportion of EPTB among new cases in Darfur conflict zone
in Sudan (2004–2014) (35%) [31], in the globe (14%), and in Sudan (26%) in 2017 [1]. The
higher proportion of EPTB in the refugee settlements can be due to demographic factors
(age, sex), origin of refugee population, host factors (immune status due to comorbidities
such as HIV coinfection) [32, 33], or due to pathogen factor (phenotypes of the tubercle
bacilli) [34]. Thus, operation research aimed to investigate the factors attributed to the
higher and increased trend in EPTB in the refugee settlements is recommended.
TB largely affects productive age groups. Similar to 2018 WHO TB report [1] and
studies done in other developing countries [35, 36], our study findings also showed that
the highest notified cases were in the age groups 15–34 (30.4%) and 35–54 (26.0%)
years (Table 1). Thus, TB programs should strengthen case-finding efforts focusing on
these age groups.
High childhood TB is an indication of high missed cases among adults and continuity
of TB transmission [23]. According to the 2018 WHO report, 14.1% of TB cases notified
in Sudan were of children (<15 years) [1]. In the refugee camps the contribution of
children to total notified TB cases increased from 8.4% in 2014 to 34.3% in 2017. The
remarkable increment in childhood TB in 2017 in the refugee camps was largely due
to the availability of Gene Xpert in Al Kashafa. It is expected that childhood TB is
misdiagnosed, overestimated, and/or underreported [2].
4.2. Treatment outcomes
TB treatment outcome is a good indicator for the overall quality of TB program and in
particular the TB treatment program [19]. According to the WHO End TB global plan,
at least 90% of all TB cases on treatment need to achieve treatment success rate by
2020 [2]. In the refugee camps, on average 75.7% (range 63.5–86.2%) of the TB cases
achieved treatment success during the study period.
By 2017, the treatment success rate in the refugee camps (63.5%) was lower than that
of the national/Sudan achievement in 2017 (78%) [1] and the WHO global target (≥90%)
[1]. Overall, the treatment success rate in the three refugee camps (range 63.5–86.2%)
was comparable to the findings among smear positive pulmonary TB (65–66%) in Darfur
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conflict zones in Sudan over 10 years (2004–2014) [24], and to treatment success rate
among refugees in different parts of the world (63.6 to 77.5%) [23–28].
The declining trend in treatment success rate in the refugee camps started in 2016,
and this was probably due to the increase in influx of new refugees in 2016 and 2017
and high mobility of the refugees. This was due to high LTFU, mortality, and unevaluated
treatment outcomes, which called for action by the refugee health and NTP. Overall, the
mean treatment failure (0.3%), LTFU (11.4%), and died (6.6%) in the refugee camps (Table
3) were comparable to the reports from other refugee camps in different countries
which showed 4.6–10.9% death rate, 7.1–27.3% LTFU, and 1.3–2.0% treatment failure
[8, 26, 27]. In summary, the low TB treatment success rate in the refugee health facilities
indicated the need to improve the TB treatment program, which includes improving
documentation, provision of training to healthcare workers, supportive supervision,
follow-up sputum smear and culture examination, supplementary nutritional support,
and racing of LTFU cases through the engagement of community health workers.
5. Conclusion
The proportion of EPTB (from 29.4 to 39.3%) and TB <15 years (from 8.4 to 34.3%)
increased over the study period. TB treatment success rate was at a range 63.5–86.2%.
The 2017 treatment success rate in the refugee camps (63.5%) was lower than the report
for Sudan (78%) and the End TB target for 2020 (≥90%), which needs to be addressed.
There was a high LTFU, mortality, and non-evaluation, which showed that there was
a gap in the TB treatment program in the refugee heath facilities. Future research is
recommended to investigate the increase in EPTB.
The study has generated useful evidence of treatment outcomes of notified TB case
from 2014 to 2017 that will support to plan effective TB care and prevention programs
in the refugee camps in Sudan. However, as this study was conducted retrospectively
based on secondary data, it had some limitations. Although, socioeconomic factors
(occupation, education, and income level), health system factors, and patient-related
factors were reported to be associated with unsuccessful treatment outcome in other
studies, we were not able to include these variables in our analysis as we used sec-
ondary data. We used only independent variables available in the Unit TB register to
assess factors associated with unsuccessful treatment outcomes.
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TB case notification: TB is diagnosed in a patient and is reported within the national
TB surveillance system.
TB cases: A patient in whom TB has been diagnosed. A TB case is defined as:
DOI 10.18502/sjms.v16i2.9293 Page 268
Sudan Journal of Medical Sciences Tsegay Legesse et al
(i) A bacteriologically confirmed TB case: is one from whom a biological specimen is
positive by smear microscopy, culture, or WHO-approved rapid diagnostics (such
as Xpert MTB/RIF).
(ii) A clinically diagnosed TB case: is one who does not fulfil the criteria for bacte-
riological confirmation but has been diagnosed with active TB by a clinician or
other medical practitioner who has decided to give the patient a full course of TB
treatment.
Bacteriologically confirmed or clinically diagnosed cases of TB are also classified
according to anatomical site of disease, history of previous treatment, drug resistance,
and HIV status.
Classification based on anatomical sites:
(i) Pulmonary tuberculosis (PTB): any bacteriologically confirmed or clinically diag-
nosed case of TB involving the lung parenchyma or the tracheobronchial tree.
(a) Pulmonary TB positive (PTB+): bacteriologically confirmed PTB cases using
available confirmatory diagnostic.
(b) Pulmonary TB negative (PTB–): clinically diagnosed PTB cases.
(ii) Extrapulmonary tuberculosis (EPTB): any bacteriologically confirmed or clinically
diagnosed case of TB involving organs other than the lungs
Classification based on history of previous TB treatment (patient registration
group):
(i) New TB patients: are those who have never been treated for TB or have taken
anti-TB drugs for less than one month.
(ii) Previously treated TB patients: are those who have received one month or more
of anti-TB drugs in the past. They are further classified by the outcome of their
most recent course of treatment as follows:
(a) Relapse patients: are those who have previously been treated for TB, were
declared cured, or the treatment was completed at the end of their most recent
course of treatment but and are now diagnosed with a recurrent episode of
TB (either a true relapse or a new TB caused by reinfection).
(b) Treatment after failure patients: are those who have previously been treated
for TB and whose treatment failed at the end of their most recent course of
treatment.
DOI 10.18502/sjms.v16i2.9293 Page 269
Sudan Journal of Medical Sciences Tsegay Legesse et al
(c) Treatment after loss to follow-up patients: are those who have previously
been treated for TB and were declared LTFU at the end of their most recent
course of treatment. (These were previously known as treatment after default
patients.)
(d) Other previously treated patients: are those who have previously been
treated for TB but whose outcome after their most recent course of treatment
is unknown or undocumented.
(e) Transfer in: a patient who started treatment in one health facility (reporting
unit) and was then transferred to another health facility (reporting unit) to
continue treatment.
Classification based on TB treatment outcomes for drug sensitive-TB:
(i) Cured: a pulmonary TB patient with bacteriologically confirmed TB at the begin-
ning of treatment whowas smear- or culture-negative in the last month of treatment
and on at least one previous occasion.
(ii) Treatment completed: a TB patient who completed treatment without evidence of
failure BUT with no record to show that sputum smear or culture results in the last
month of treatment and on at least one previous occasion were negative either
because tests were not done or because results are unavailable.
(iii) Treatment failed: a TB patient whose sputum smear or culture is positive at month
5 OR later during treatment.
(iv) Lost to follow-up (LTFU): a TB patient who did not start treatment OR whose
treatment was interrupted for two consecutive months or more.
(v) Died: a TB patient who dies for any reason before starting OR during the course
of treatment.
(vi) Not evaluated: a TB patient for whom no treatment outcome is assigned. This
includes cases “transferred out” to another treatment unit as well as cases for
whom the treatment outcome is unknown to the reporting unit.
(a) Successful treatment: sum of cured and treatment completed outcomes.
(b) Unsuccessful treatment: sum of died, treatment failed, and LTFU outcomes.
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TABLE 1: Characteristics of notified TB cases in Al Kashafa, Wadsherify, and Shagarab refugee camps, Sudan,
2014–2017 (N = 710).
Characteristic 2014, N (%) 2015, N (%) 2016, N (%) 2017, N (%) Total
(2014–2017)
Total TB cases (row, %) 143 (20.1) 80 (11.3) 146 (20.6) 341 (48.0) 710 (100)
Mean age (SD), yr 38.2 (19.1) 42.0 (21.6) 39.5 (19.0) 28.2 (21.4) 34.1 (21.4)
By age groups
<15 12 (8.4) 8 (10.0) 20 (13.7) 117 (34.3) 157 (22.1)
15–24 30 (21.0) 8 (10.0) 10 (6.9) 50 (14.7) 98 (13.8)
25–34 27 (18.9) 17 (21.3) 30 (20.1) 44 (12.9) 118 (16.6)
35–44 19 (13.3) 12 (15.0) 25 (17.1) 36 (10.6) 92 (13.0)
45–54 20 (14.0) 13 (16.3) 19 (13.0) 40 (11.7) 92 (13.0)
55–64 11(7.7) 5 (6.3) 26 (17.8) 31 (9.1) 73 (10.3)
>=65 24 (16.8) 17 (21.3) 16 (11.0) 21 (6.2) 78 (11.0)
Not recorded 0 0 0 2 (0.6) 2 (0.3)
BY gender
Male 72 (50.4) 46 (57.5) 81 (55.9) 178 (52.7) 377 (53.4)
Female 71 (49.6) 34 (42.5) 64 (44.1) 160 (47.3) 329 (46.6)
Male to Female ratio 1 1.4 1.7 1.1 1.1
BY type of TB
PTB 101 (70.6) 51 (63.8) 94 (64.4) 207 (60.7) 453 (63.8)
EPTB 42 (29.4) 29 (36.2) 52 (35.6) 134 (39.3) 257 (36.2)
By diagnostic category
PTB+ 54 (37.8) 30 (37.5) 37 (25.3) 85 (24.9) 206 (29.0)
PTB– 47 (32.9) 21 (26.3) 57 (39.1) 122 (35.8) 247 (34.8)
EPTB 42 (29.4) 29 (36.2) 52 (35.6) 134 (39.3) 257 (36.2)
BY type of TB patients
New and relapse 138 (96.5) 80 (100) 141 (96.6) 321 (94.1) 680 (95.8)
Treatment after failure 4 (2.8) 0 0 1 (0.3) 5 (0.7)
Lost to follow-up to treatment 1 (0.7) 0 5 (3.4) 15 (4.4) 21 (3.0)
Others 0 0 0 4 (1.2) 4 (0.6)
New and relapse –PTB patients 97 (70.3) 51 (63.8) 89 (63.1) 189 (58.9) 426 (62.6)
Bacteriologically confirmed 51 (52.6) 30 (58.8) 36 (40.4) 76 (40.2) 193 (45.3)
Clinically diagnosed 46 (47.4) 21 (41.2) 53 (59.6) 113 (59.8) 233 (54.7)
By HIV status
Positive 1 (2.0) 4 (7.1) 3 (4.2) 6 (4.7) 14 (4.6)
Negative 47 (98.0) 52 (92.9) 68 (95.8) 122 (95.3) 289 (95.4)
Not documented 95 (66.4) 24 (30) 75 (52.4) 213 (62.5) 407 (1.6)
BY refugee camps
Al Kashafa 0 0 60 274 334 (47.0%)
Shagarab 98 41 47 20 206 (29.0%)
Wadsherify 45 39 39 47 170 (23.9%)
PTB+: smear-positive pulmonary TB; PTB–: clinically diagnosed PTB, which includes smear-negative
pulmonary TB and smear not done/unknown.
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TABLE 2: TB treatment outcome of all TB cases registered in Al Kashafa, Wadsherify, and Shagarab refugee




2014 (n = 143)
N (%)




2017 (n = 341)
N (%)
Total (n = 710)
N (%)
Cured 38 (26.6) 28 (35.0) 25 (17.1) 42 (10.6) 133 (18.7)
Treatment
Completed
74 (51.7) 41 (51.2) 96 (65.8) 194 (56.9) 405 (57.0)
Treatment failed 0 0 1 (0.7) 1 (0.3) 2 (0.3)
LTFU 12 (8.4) 3 (3.8) 12 (8.2) 54 (15.8) 81 (11.4)
Died 6 (4.2) 3 (3.8) 9 (6.2) 29 (8.5) 47 (6.6)
Not evaluated 13 (9.1) 5 (6.2) 3 (2.0) 21 (6.2) 42 (5.9)
Success rate 112 (78.3) 69 (86.2) 121 (82.9) 252 (63.5) 538 (75.7)
TABLE 3: Demographic and clinical characteristics associated with unsuccessful TB treatment outcomes








X2, P-value Bivariate analysis Multivariable analysis




Female 250 (80.7) 60 (19.3) 0.002 1
Male 285 (80.5) 69 (19.5) 0.9 1.02 (0.7–1.5) 0.9
Age group
<15 110 (71.9) 43 (28.1) 1
15–24 80 (86.0) 13 (14.0) 15.2 0.4 (0.2–0.8) 0.01 0.4 (0.2–0.9) 0.02
25–34 91 (84.3) 17 (15.7) 0.03 0.5 (0.3–0.9) 0.02 0.5 (0.3–1.0) 0.06
35–44 70 (81.4) 16 (18.6) 0.6 (0.3–1.1) 0.1 0.6 (0.3–1.2) 0.2
45–54 69 (84.1) 13 (15.9) 0.5 (0.2–0.96) 0.04 0.5 (0.3–1.0) 0.06
55–64 59 (83.1) 12 (16.9) 0.5 (0.3–1.1) 0.07 0.6 (0.3–1.2) 0.1
>=65 59 (79.7) 15 (20.3) 0.7 (0.3–1.3) 0.2 0.7 (0.3–1.3) 0.2
Pretreatment weight, Kg*
>40 188 (81.0) 44 (19.0) 1.2 1
<40 78 (75.7) 25 (24.3) 0.2 1.4 (0.7–2.4) 0.2
Type of TB
PTB– 169 (73.8) 60 (26.2) 1 1
PTB+ 162 (83.9) 31 (16.1) 10.1 0.5 (0.3–0.8) 0.01 0.6 (0.4–1.1) 0.07
EPTB 207 (84.1) 39 (15.9) 0.006 0.5 (0.3–0.8) 0.006 0.5 (0.3–0.9) 0.009
HIV status
Negative 238 (88.5) 31 (11.5) 1.5 1 0.2
Positive 10 (76.9) 3 (23.1) 0.2 2.3 (0.6–8.8)
PTB+: smear-positive pulmonary TB; PTB–: clinically diagnosed PTB, which includes smear-negative
pulmonary TB and smear not done/unknown; OR: odds ratio; CI: Confidence interval; 1:00, Reference; X2:
Chi-square.
*Analysis done for adults aged ≥15 years.
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